ABNX-100 is the strategic extension into ophthalmology of CER-001, ABIONYX Pharma's proprietary platform based on the only recombinant apolipoprotein A-I. Derived directly from this technology, this molecule capitalizes on a differentiated mechanism of action focused on lipid regulation and inflammation resolution, two key levers in severe eye diseases.
Designed to target uveitis, an intraocular inflammation that can lead to irreversible vision loss, ABNX-100 is part of a systemic approach that aims to restore ocular homeostasis by acting on both inflammatory processes and epithelial tissue repair, with the goal of significantly improving vision function.
The active ingredient directly benefits from the data accumulated with CER-001, whose anti-inflammatory and reparative properties have already been demonstrated, particularly in complex clinical contexts. This technological continuity reduces the development risk and reinforces the scientific credibility of the program.
In a field where therapeutic options remain limited and are often associated with significant side effects, ABNX-100 paves the way for a new generation of systemic treatments in ophthalmology. Positioned at the intersection of biological innovation and unmet medical needs, this molecule represents a major value driver for ABIONYX Pharma and offers real hope for patients with inflammatory eye diseases.